SDAI Limited has received shareholder approval to diversify its core business into the biotechnology sector, aiming to capitalise on the rapidly growing anti-ageing market. This decision was confirmed during an extraordinary general meeting held on 30 April 2026.
The biotechnology industry is expanding swiftly, driven by global population growth and advancements in longevity science. The global anti-ageing market, valued at US$80b in 2025, is projected to reach US$137.1b by 2035. In Singapore, this growth is supported by the government’s Research, Innovation and Enterprise 2030 Plan, which will invest S$37b in research over the next five years.
SDAI’s strategic initiatives include a partnership with LiveBeyond for anti-ageing research, the launch of the Bluecode Biotech B-III skincare series, and a joint venture with Hubei Qiai to expand moxibustion products across ASEAN. Executive Chairperson Hao Dongting stated, “The Group is now well positioned to chart a new growth trajectory, following the successful transformation of our business into a biotechnology-focused platform specialising in anti-ageing and healthcare.”
The company aims to establish a first-mover advantage in Asia’s longevity sector and position itself as a leading brand in the anti-ageing industry. With a focus on skin anti-ageing, supplements, and moxibustion health management, SDAI is poised to transform healthy longevity into a scalable consumer offering. Whilst still in the early stages, SDAI is confident in achieving sustainable growth through this diversification.
